We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
22 Dec 2014 Genus PLC GNS Liberum Capital Buy 0.00 1,285.00 1,400.00 1,400.00 Reiterates SP TARGET 1400p
Can anyone tell me why the SP dropped from 1400p last January to 950p by the April ??
01 Dec 2014 Genus PLC GNS Liberum Capital Buy 1,291.00 1,291.00 1,400.00 1,400.00 Reiterates SP targer 1400p
<b>70% of Chickens have bacteria</b>..XMAS TRADE!!.... Beef = GNS GENUS Pork = CWK CRANSWICK as alternatives for chrissy dinner and parties etc. GNS as the better chart and Ive found out they do both Beef and Pork. Long on GNS https://pbs.twimg.com/media/B3dQhd6CAAEETIu.jpg
GNS GENUS...Numis starts with add rating; price target 1290p
My Day 3 - from a low of 935p to end on 967p and that in another falling market - welcome to the oscillating world of Genus !
Good first day..disasterous second ..drop of 5.91%.... 1022p one minute 940p by day close
Finally dipped my toes in at 960p and a good first day...first hurdle 1000p ...let us see how that goes
so much potential..these have to be cheap now? dont they ?
Chairman and ceo both bought shares on 03/04/2014
Opened at 1014 but ended at 960 in another falling market..down 2.59% to another new low
another new low today in a falling market ...any short climb to 1000p soon falls back
nop..it just keeps on falling ...
is today showing signs of the bottom?
400 point drop over 2 months and still no bottom - usa pig virus and china problems ...
The acquisition is expected to be modestly accretive to earnings in FY2014 and will add more significantly to earnings as synergies are realised over the first 24 months. At full run rate, synergies of US$11m (£6.9m) per annum are anticipated (including Genus' share of synergies in Brazil) as the operations of Génétiporc are combined with Genus' PIC business. http://www.lse.co.uk/share-regulatory-news.asp?shareprice=GNS&ArticleCode=gpakeq3c&ArticleHeadline=Genus_to_Acquire_Gntiporc
Seemed good enough for Hyboy on iii wonder if it's good enough for me.
N+1 Singer stuck with its "buy" recommendation on pig semen company Genus (GNS) with a target price of 1,678p. The broker believes that the company is in a good position to benefit from the long-term steady increase in demand for animal protein, which has already driven a "remarkably consistent" financial performance. The broker also notes the appointment of Stephen Wilson, currently CFO at Misys, as FD who will take up the post in March next year and believes he has the experience to drive growth in the long-term. The shares lost 11p to 1,399p.
Chief Executive of Genus, Karim Bitar, has welcomed Wilson to the board. "We are delighted that Stephen will be joining Genus," Bitar said. "He brings strong financial and business development skills, and will be a valuable business partner, with his experience of working in large global enterprises and his record of building strong finance teams. I am looking forward to working closely with Stephen in continuing to execute our exciting and ambitious growth strategy."
Genus announced Thursday that Group Finance Director John Worby will be stepping down after eight years at the leading global animal genetics firm. Worby - who joined the board in 2004 as non-executive director before being appointed the group finance director - is set to retire from the board of the FSTE 250 company next March as he focuses on his non-executive portfolio. "During his time at Genus, John has been an invaluable member of the Board in both his Non-Executive and Group Finance Director capacities," Chairman Bob Lawson said in a statement. "His vast knowledge and experience supporting quoted companies has helped Genus to develop strong relationships with its shareholders and has been a huge source of strength for the CEOs with whom he has worked. We are very grateful to John for all his contributions over the years and on behalf of the board, we wish him well in his retirement. " Stephen Wilson, who is currently Executive Vice President and Chief Financial Officer of financial software provider Misys, will step into Worby's shoes. Wilson was Vice President and CFO of IBM UK prior to joining Misys. He is also a fellow of the Chartered Institute of Management Accountants and is a non-executive director of Xchanging.
In The Times, the Tempus column kicks off with animal semen producer Genus, which dropped yesterday as investors worried about the price of feedstocks like corn in the agricultural sector. But Genus has been a major success story, providing the gene pool to increase yields for pig and cow farmers across the globe. Its recent moves into China also bodes well. Tempus believes, at 24 times earnings, there is a case to take profits on the stock and sell.
Headline profit before tax rose 19% (22% in CC terms) to £46.5m from £39.0m the previous year, while statutory profit before tax rose 33% to £54.4m from £40.8m a year earlier. Investment analysts following the stock had pencilled in a figure of £44.6m for adjusted profit before tax. Growth in volumes was the primary driver for the bull and pig semen provider. Porcine volumes were up 7% and bovine volumes up 8%. Growth was particularly strong in Asia, Latin America and the porcine business in North America, the company said. The full-year dividend has been increased by 10% to 14.6p from 13.3p the previous year, in line with market expectations. The group conceded that market conditions remained generally favourable for Genus and its customers in the year just ended, but noted they became more challenging towards the end of the reporting period, largely because of increased feed costs in North America caused by drought conditions and by weakening global commodity dairy prices. These conditions are likely to have an impact on a number of Genus's customers in the year ahead, which may lead to some slowing in demand.
Record results from Genus, the animal genetics company, topped full-year sales and profits expectations on the back of strong performances in Asia, North America and Latin America. Revenue in the year to June 30th rose 10%, or 12% in constant currency (CC) terms, to £341.8m from £309.9m the year before. The market had been expecting revenue of around £333.2m.
We expect to hear more about plans in China, particularly with the announcement of the major JV [joint venture] with Besun, which will deliver genetics to 10m slaughter pigs when in full operation," the broker added. As for Dechra, the market is expecting profit before tax of £31.1m on revenue of £420.2m. Earnings per share are tipped to rise 19% to 37.03p, paving the way for the full-year dividend to be upped to around 12.16p from 10.97p last year.
Peel Hunt says emerging markets growth should be offsetting higher feed prices at Genus. It is forecasting a 15% improvement in profits, with strong growth across a number of emerging markets. The key issue currently is the rise in feed prices, Peel Hunt believes. "This will have a direct impact on Genus's feed costs of around £1m, but it will also affect its customers. Some customers may well struggle in the short term, but generally higher feed prices are good news for Genus as it accelerates the trend to industrialisation of the industry and reinforces the benefits of genetics in improving feed conversion," the broker predicts.